Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Glioma Clinical Trial

Official title:

Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT05392374
• Other study ID #: ONC016
• Status: No longer available

Study information

• Verified date: May 2022
• Source: Chimerix
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

This is an intermediate-size expanded access protocol to provide ONC201 to patients with diffuse intrinsic pontine gliomas who cannot access ONC201 through clinical trials.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Gender: All
• Age group: 6 Months to 18 Years

Eligibility

Inclusion Criteria:

1. Patient with DIPG who failed at least one line of prior therapy such as focal radiation therapy

2. Patient must be > than 6 months and < 18 years of age.

3. Confirmed evidence of disease progression from immediately prior therapy or refractory to the immediately prior treatment.

4. Karnofsky/Lansky performance status = 50.

5. Adequate organ and marrow function as defined below:

1. Absolute neutrophil count =1,000/mm3 without growth factor use = 7 days prior to treatment (cycle 1 day 1, C1D1)

________________________________________________________________________________ CONFIDENTIAL Page 3 of 45

2. Hemoglobin>8.0 mg/dL without red blood cell transfusion = 3 days prior to C1D1

3. Total serum bilirubin<1.5 X upper limit of normal (ULN)

4. AST (SGOT)/ALT (SGPT)=2 X ULN;; = 5 X ULN if there is liver involvement secondary to tumor

5. Serum creatinine= 1.5 X ULN (OR creatinine clearance = 60 mL/min/1.73 m2)

6. Ability to understand and the willingness to sign a written informed consent document by the patient or their legal guardian.

7. If patient is of child--bearing age, female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate.

8. Patient must be able to swallow capsules and retain orally administered medication.

Exclusion Criteria:

1. Body weight >10Kg.

2. Known active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV).

3. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)--related illness.

4. Active or prior plasma cell leukemia (defined as either 20% of peripheral WBC comprised of plasma/CD138+ cells or an absolute count of 2 x 10^9/L).

5. Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia.

6. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism.

7. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the patient inappropriate for entry into the study.

Related Conditions & MeSH terms

• Diffuse Intrinsic Pontine Glioma
• Glioma

Intervention

Drug:
• ONC201
ONC201 is an oral, small molecule selective antagonist of DRD2

Locations

Country	Name	City	State
United States	Albany Medical Center	Albany	New York
United States	University of Michigan	Ann Arbor	Michigan
United States	Children's Healthcare of Atlanta	Atlanta	Georgia
United States	Children's Hospital Colorado	Aurora	Colorado
United States	NYU Langone Health	New York	New York
United States	Stephen Hassenfeld Children's Center for Cancer and Blood Disorders (NYU)	New York	New York
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	University of Rochester Medical Center	Rochester	New York
United States	University of California San Francisco	San Francisco	California
United States	Children's National Medical Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Chimerix

Country where clinical trial is conducted

United States,